Tenax Therapeutics, Inc. (TENX) - 10-K Summary
Business Context and Reporting Period
Company: Tenax Therapeutics, Inc.
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies. The company utilizes a clinician-driven approach to develop novel therapies for pulmonary hypertension, primarily leveraging repurposed drugs with established safety profiles.
Key Assets: The company holds exclusive rights to develop and commercialize oral and subcutaneous formulations of levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) via a license with Orion Corporation. It also holds rights to a modified-release formulation of imatinib (TNX-201) for pulmonary arterial hypertension (PAH), though this program is currently deprioritized.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(52.6) million | $(17.6) million |
| Operating Expenses | $56.4 million | $19.5 million |
| Research & Development (R&D) | $32.7 million | $12.7 million |
| General & Administrative (G&A) | $23.7 million | $6.8 million |
| Cash and Cash Equivalents (Year-End) | $97.6 million | $94.9 million |
| Working Capital | $97.1 million | $92.0 million |
| Accumulated Deficit | $(367.5) million | $(314.9) million |
Note: The company has no debt and no interest expense for the year ended December 31, 2025.
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased 189% to $56.4 million, driven by the acceleration of Phase 3 clinical trials. R&D expenses rose 157% to $32.7 million, primarily due to costs associated with the ongoing LEVEL trial and the initiation of the LEVEL-2 trial in December 2025.
- Stock-Based Compensation: A significant driver of the expense increase was stock-based compensation, which totaled $19.2 million in 2025 compared to $1.1 million in 2024. This was due to option grants made in late 2024 and throughout 2025.
- Financing Activity: The company raised $25.0 million in gross proceeds via a private placement in March 2025. Additionally, $15.3 million was received from the exercise of warrants and pre-funded warrants during the year.
- Interest Income: Interest income doubled to $3.8 million, reflecting higher interest rates and increased cash balances from recent capital raises.
Guidance, Outlook, and Risks
Outlook and Capital Runway: Management believes that existing cash and cash equivalents of $97.6 million (as of Dec 31, 2025), combined with $14.5 million received from warrant exercises subsequent to year-end, are sufficient to fund operations through at least the end of 2027. The company plans to complete the LEVEL and LEVEL-2 Phase 3 trials and submit marketing authorization applications thereafter.
Clinical Progress:
- LEVEL Trial: Target enrollment of 230 patients was achieved in March 2026. A blinded sample size re-estimation confirmed the trial is powered at over 90% to detect the primary endpoint.
- LEVEL-2 Trial: Initiated in December 2025; a global Phase 3 study targeting approximately 540 patients.
Key Risks and Contingencies:
- Capital Requirements: The company will require substantial additional funding to complete trials, file for regulatory approval, and commercialize products. Failure to secure capital could force delays or termination of operations.
- Clinical Uncertainty: Outcomes of the Phase 3 trials are uncertain. Failure to meet primary endpoints would materially harm the business.
- Third-Party Dependence: The company relies entirely on third-party manufacturers (Orion Corporation is the sole source for TNX-103) and CROs for clinical trials.
- Intellectual Property: Success depends on maintaining patent protection and avoiding infringement claims. The license with Orion includes milestone payments totaling up to $55.0 million upon FDA approval and sales milestones.
Investor Verification Checklist
- Cash Burn Rate: Verify the monthly cash burn rate against the $97.6 million cash balance to confirm the "end of 2027" runway estimate.
- Warrant Exercises: Confirm the $14.5 million in post-year-end warrant exercises and the resulting dilution impact on share count.
- Stock-Based Compensation: Review the $19.2 million stock-based compensation expense and the remaining unrecognized costs ($14.7 million) to understand future non-cash expense pressure.
- Orion License Terms: Review the specific milestone triggers and royalty rates in the amended license agreement with Orion Corporation, particularly the $10M FDA approval milestone and $45M sales milestones.
- LEVEL Trial Enrollment: Monitor the actual enrollment progress of the LEVEL-2 trial initiated in late 2025 against the target of 540 patients.